Shots:Relmada has reported initial P-II trial data assessing NDV-01 in 20 pts with HG-NMIBC (8 BCG-naïve, 12 BCG-unresponsive), where 2 pts had CIS & 18 had papillary disease (Ta/T1); 26 pts are enrolled, with 20 reaching 3mos. & 7 reaching 6mos. assessmentsTrial showed 85% ORR, 83.3% HGRFS in Ta/T1, & 100% CR in…
Shots:Relmada acquired the Sepranolone from Asarina for $3.12M via an asset purchase agreement to develop it as a potential treatment for Tourette syndrome (TS) & other compulsive disorders
Sepranolone (10mg, BIW, SC) is a GABAA-modulating steroid antagonist that is being investigated in a P-IIa trial, assessing it with SoC vs SoC alone in…

